Clinical TrialJun 26, 2026, 04:13 PM
Vaxart BARDA Funding Reduced to $345M; $29M Released for Data
AI Summary
Vaxart, Inc. entered into a modification to its Project Agreement with Advanced Technology International (ATI), funded by BARDA, for its oral pill COVID-19 vaccine candidate trial. The total funding available has been reduced to approximately $345 million, a decrease of about $116 million, due to a 50% reduction in trial participants. However, the modification also releases approximately $29 million for trial completion and exploratory analyses, enabling the company to report 12-month data from the Sentinel Cohort in the coming weeks and from the main cohort in the first half of 2027.
Key Highlights
- BARDA funding for COVID-19 vaccine trial reduced to $345 million.
- Total funding decreased by approximately $116 million from prior modification.
- Reduction follows an approximately 50% decrease in trial participants.
- Approximately $29 million released for trial completion and exploratory analyses.
- 12-month data from 400-participant Sentinel Cohort expected in coming weeks.
- 12-month data from 5,085-participant main cohort expected in H1 2027.
Price Impact
More from VXRT